Company intelligence / Profile preview

Shanghai Reinovax Biologics Co., Ltd.

Shanghai, Shanghai, Chinareinovax.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company's lead product, a 24-valent pneumococcal polysaccharide conjugate vaccine (PCV-24), has completed Phase I trials and is currently in Phase II clinical trials for pneumococcal infections in China. Phase I was completed on November 15, 2024, and Phase II trials began on April 20, 2024, targeting adults and the elderly.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: VaccinesConjugate vaccinesPolysaccharide vaccinesmRNA
Industry: Biotech

Drug pipeline

2 assets

Reinovax PCV24

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Reinovax Biologics Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Reinovax Biologics Co., Ltd..

Explore the full profile